We additionally generated an anti-E3–anti-CD19 molecule to serve as a non-AML-targeting control construct (CD19 KD = 4.9 nM) (Supplementary Fig. 1A and 2A). The gene discussed is CD19; the disease is acute myeloid leukemia.